{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:57:42Z","timestamp":1790791062219,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T00:00:00Z","timestamp":1341273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/nrgastro.2012.125","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T03:58:43Z","timestamp":1341287923000},"page":"496-503","source":"Crossref","is-referenced-by-count":165,"title":["Paradoxical inflammation induced by anti-TNF agents in patients with IBD"],"prefix":"10.1038","volume":"9","author":[{"given":"Isabelle","family":"Cleynen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,3]]},"reference":[{"key":"BFnrgastro2012125_CR1","first-page":"233","volume":"56","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet, L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol. Dietol. 56, 233\u2013243 (2010).","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"BFnrgastro2012125_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1592\/phco.30.4.339","volume":"30","author":"A Wiens","year":"2010","unstructured":"Wiens, A., Venson, R., Correr, C. J., Otuki, M. F. & Pontarolo, R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30, 339\u2013353 (2010).","journal-title":"Pharmacotherapy"},{"key":"BFnrgastro2012125_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1445-5994.2008.01639.x","volume":"38","author":"MR Reed","year":"2008","unstructured":"Reed, M. R. & Taylor, A. L. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 38, 781\u2013789 (2008).","journal-title":"Intern. Med. J."},{"key":"BFnrgastro2012125_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb, A. B. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534\u2013542 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrgastro2012125_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2004.020719","volume":"63","author":"P Mease","year":"2004","unstructured":"Mease, P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann. Rheum. Dis. 63, 755\u2013758 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrgastro2012125_CR6","first-page":"14","volume":"84","author":"A Menter","year":"2009","unstructured":"Menter, A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 84, 14\u201324 (2009).","journal-title":"Cutis"},{"key":"BFnrgastro2012125_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"KA Papp","year":"2005","unstructured":"Papp, K. A. et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304\u20131312 (2005).","journal-title":"Br. J. Dermatol."},{"key":"BFnrgastro2012125_CR8","first-page":"672","volume":"29","author":"F Heldmann","year":"2011","unstructured":"Heldmann, F. et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 29, 672\u2013680 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrgastro2012125_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/rheumatology\/keq285","volume":"50","author":"PJ Mease","year":"2011","unstructured":"Mease, P. J. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology (Oxford) 50, 261\u2013270 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrgastro2012125_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1874467211003030145","volume":"3","author":"B Ngo","year":"2010","unstructured":"Ngo, B. et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr. Mol. Pharmacol. 3, 145\u2013152 (2010).","journal-title":"Curr. Mol. Pharmacol."},{"key":"BFnrgastro2012125_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/eci.10.49","volume":"6","author":"PV Voulgari","year":"2010","unstructured":"Voulgari, P. V. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev. Clin. Immunol. 6, 721\u2013733 (2010).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"BFnrgastro2012125_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1586\/eci.10.67","volume":"6","author":"S Ramiro","year":"2010","unstructured":"Ramiro, S., van Tubergen, A. M. & Landewe, R. B. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Rev. Clin. Immunol. 6, 713\u2013720 (2010).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"BFnrgastro2012125_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G D'Haens","year":"1999","unstructured":"D'Haens, G. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116, 1029\u20131034 (1999).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012125_CR14","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275\u20132285 (2006).","journal-title":"JAMA"},{"key":"BFnrgastro2012125_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"HH Fidder","year":"2009","unstructured":"Fidder, H. H. et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58, 501\u2013508 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2012125_CR16","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos, X. et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford) 50, 1690\u20131699 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrgastro2012125_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","volume":"50","author":"W Kievit","year":"2011","unstructured":"Kievit, W. et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50, 196\u2013203 (2011).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrgastro2012125_CR18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3899\/jrheum.101009","volume":"38","author":"Y Komano","year":"2011","unstructured":"Komano, Y. et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J. Rheumatol. 38, 1258\u20131264 (2011).","journal-title":"J. Rheumatol."},{"key":"BFnrgastro2012125_CR19","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3748\/wjg.15.2067","volume":"15","author":"F Hoentjen","year":"2009","unstructured":"Hoentjen, F. & van Bodegraven, A. A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 15, 2067\u20132073 (2009).","journal-title":"World J. Gastroenterol."},{"key":"BFnrgastro2012125_CR20","first-page":"546","volume":"8","author":"LH Kircik","year":"2009","unstructured":"Kircik, L. H. & Del Rosso, J. Q. Anti-TNF agents for the treatment of psoriasis. J. Drugs Dermatol. 8, 546\u2013559 (2009).","journal-title":"J. Drugs Dermatol."},{"key":"BFnrgastro2012125_CR21","first-page":"31","volume":"30","author":"TE Markatseli","year":"2012","unstructured":"Markatseli, T. E., Alamanos, Y., Saougou, I., Voulgari, P. V. & Drosos, A. A. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin. Exp. Rheumatol. 30, 31\u201338 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrgastro2012125_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ibd.20956","volume":"15","author":"JF Colombel","year":"2009","unstructured":"Colombel, J. F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308\u20131319 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR23","first-page":"178","volume":"5","author":"DR Adams","year":"2006","unstructured":"Adams, D. R., Buckel, T. & Sceppa, J. A. Infliximab associated new-onset psoriasis. J. Drugs Dermatol. 5, 178\u2013179 (2006).","journal-title":"J. Drugs Dermatol."},{"key":"BFnrgastro2012125_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/ibd.20137","volume":"13","author":"E Angelucci","year":"2007","unstructured":"Angelucci, E., Cocco, A., Viscido, A., Vernia, P. & Caprilli, R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm. Bowel Dis. 13, 1059\u20131061 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR25","first-page":"380","volume":"34","author":"JD Cohen","year":"2007","unstructured":"Cohen, J. D. et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol. 34, 380\u2013385 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrgastro2012125_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer, A. N., Guerrero, K. T., Henning, J. S. & Battafarano, D. F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59, 996\u20131001 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrgastro2012125_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nrgastro.2010.7","volume":"7","author":"LS Conklin","year":"2010","unstructured":"Conklin, L. S., Cohen, B., Wilson, L., Cuffari, C. & Oliva-Hemker, M. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7, 174\u2013177 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012125_CR28","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ibd.20450","volume":"14","author":"M Costa-Romero","year":"2008","unstructured":"Costa-Romero, M., Coto-Segura, P., Suarez-Saavedra, S., Ramos-Polo, E. & Santos-Juanes, J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm. Bowel Dis. 14, 1462\u20131463 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2310\/7750.2008.07080","volume":"13","author":"PL English","year":"2009","unstructured":"English, P. L. & Vender, R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J. Cutan. Med. Surg. 13, 40\u201342 (2009).","journal-title":"J. Cutan. Med. Surg."},{"key":"BFnrgastro2012125_CR30","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/j.cgh.2010.04.015","volume":"8","author":"J Goldstein","year":"2010","unstructured":"Goldstein, J. & Levine, J. Infliximab-induced psoriaform rash. Clin. Gastroenterol. Hepatol. 8, A24 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012125_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/MPG.0b013e3181f3d9ab","volume":"52","author":"G Hiremath","year":"2011","unstructured":"Hiremath, G., Duffy, L. & Leibowitz, I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 52, 230\u2013232 (2011).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"BFnrgastro2012125_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.crohns.2010.11.001","volume":"5","author":"M Iborra","year":"2011","unstructured":"Iborra, M., Beltran, B., Bastida, G., Aguas, M. & Nos, P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J. Crohns Colitis 5, 157\u2013161 (2011).","journal-title":"J. Crohns Colitis"},{"key":"BFnrgastro2012125_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","volume":"32","author":"AC Laga","year":"2010","unstructured":"Laga, A. C., Vleugels, R. A., Qureshi, A. A. & Velazquez, E. F. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am. J. Dermatopathol. 32, 568\u2013573 (2010).","journal-title":"Am. J. Dermatopathol."},{"key":"BFnrgastro2012125_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/039463200902200331","volume":"22","author":"E Manni","year":"2009","unstructured":"Manni, E. & Barachini, P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int. J. Immunopathol. Pharmacol. 22, 841\u2013844 (2009).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"BFnrgastro2012125_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.gcb.2009.10.021","volume":"34","author":"F Medkour","year":"2010","unstructured":"Medkour, F. et al. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 34, 140\u2013141 (2010).","journal-title":"Gastroenterol. Clin. Biol."},{"key":"BFnrgastro2012125_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1468-3083.2007.02335.x","volume":"22","author":"E Papadavid","year":"2008","unstructured":"Papadavid, E., Gazi, S., Dalamaga, M., Stavrianeas, N. & Ntelis, V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J. Eur. Acad. Dermatol. Venereol. 22, 380\u2013382 (2008).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFnrgastro2012125_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5021\/ad.2009.21.1.60","volume":"21","author":"BC Park","year":"2009","unstructured":"Park, B. C. et al. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann. Dermatol. 21, 60\u201362 (2009).","journal-title":"Ann. Dermatol."},{"key":"BFnrgastro2012125_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000107622","volume":"215","author":"B Passarini","year":"2007","unstructured":"Passarini, B. et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 215, 295\u2013300 (2007).","journal-title":"Dermatology"},{"key":"BFnrgastro2012125_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-2230.2005.01882.x","volume":"30","author":"L Peramiquel","year":"2005","unstructured":"Peramiquel, L. et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin. Exp. Dermatol. 30, 713\u2013714 (2005).","journal-title":"Clin. Exp. Dermatol."},{"key":"BFnrgastro2012125_CR40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2340\/00015555-0425","volume":"88","author":"L Perez-Perez","year":"2008","unstructured":"Perez-Perez, L., Caeiro, J. L., Fabeiro, J. M., Allegue, F. & Zulaica, A. Induction of pustular lesions during infliximab therapy for Crohn's disease. Acta Derm. Venereol. 88, 292\u2013293 (2008).","journal-title":"Acta Derm. Venereol."},{"key":"BFnrgastro2012125_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000095033","volume":"213","author":"D Pirard","year":"2006","unstructured":"Pirard, D., Arco, D., Debrouckere, V. & Heenen, M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 213, 182\u2013186 (2006).","journal-title":"Dermatology"},{"key":"BFnrgastro2012125_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1525-1470.2010.01267.x","volume":"27","author":"C Pourciau","year":"2010","unstructured":"Pourciau, C. & Shwayder, T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr. Dermatol. 27, 539\u2013540 (2010).","journal-title":"Pediatr. Dermatol."},{"key":"BFnrgastro2012125_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1346-8138.2007.00312.x","volume":"34","author":"H Takahashi","year":"2007","unstructured":"Takahashi, H. et al. Psoriasiform and pustular eruption induced by infliximab. J. Dermatol. 34, 468\u2013472 (2007).","journal-title":"J. Dermatol."},{"key":"BFnrgastro2012125_CR44","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/ibd.20150","volume":"13","author":"J Umeno","year":"2007","unstructured":"Umeno, J. et al. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm. Bowel Dis. 13, 1188\u20131189 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1345\/aph.1C477","volume":"38","author":"MM Verea","year":"2004","unstructured":"Verea, M. M., Del Pozo, J., Yebra-Pimentel, M. T., Porta, A. & Fonseca, E. Psoriasiform eruption induced by infliximab. Ann. Pharmacother. 38, 54\u201357 (2004).","journal-title":"Ann. Pharmacother."},{"key":"BFnrgastro2012125_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina, U. et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am. J. Clin. Dermatol. 9, 1\u201314 (2008).","journal-title":"Am. J. Clin. Dermatol."},{"key":"BFnrgastro2012125_CR47","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/ibd.21643","volume":"17","author":"DC Baumgart","year":"2011","unstructured":"Baumgart, D. C., Grittner, U., Steingraber, A., Azzaro, M. & Philipp, S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm. Bowel Dis. 17, 2512\u20132520 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR48","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","volume":"34","author":"G Cullen","year":"2011","unstructured":"Cullen, G., Kroshinsky, D., Cheifetz, A. S. & Korzenik, J. R. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment. Pharmacol. Ther. 34, 1318\u20131327 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2012125_CR49","doi-asserted-by":"publisher","unstructured":"Ettler, J., Wetter, D. A. & Pittelkow, M. R. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-alpha inhibitor therapy. Clin. Exp. Dermatol. http:\/\/dx.doi.org\/10.1111\/j.1365-22302011.04286.x .","DOI":"10.1111\/j.1365-22302011.04286.x"},{"key":"BFnrgastro2012125_CR50","first-page":"1055","volume":"146","author":"RQ Klein","year":"2010","unstructured":"Klein, R. Q., Spivack, J. & Choate, K. A. Psoriatic skin lesions induced by certolizumab pegol. Arch. Dermatol. 146, 1055\u20131056 (2010).","journal-title":"Arch. Dermatol."},{"key":"BFnrgastro2012125_CR51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","volume":"8","author":"JF Rahier","year":"2010","unstructured":"Rahier, J. F. et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin. Gastroenterol. Hepatol. 8, 1048\u20131055 (2010).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012125_CR52","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1136\/gut.2009.179606","volume":"59","author":"I Cleynen","year":"2010","unstructured":"Cleynen, I. et al. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut 59, A1 (2010).","journal-title":"Gut"},{"key":"BFnrgastro2012125_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison, M. J. et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68, 209\u2013215 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrgastro2012125_CR54","doi-asserted-by":"publisher","unstructured":"Dalkilic, E. et al. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod. Rheumatol. http:\/\/dx.doi.org\/10.1007\/s10165-011-0590-9 .","DOI":"10.1007\/s10165-011-0590-9"},{"key":"BFnrgastro2012125_CR55","first-page":"223","volume":"143","author":"GC de Gannes","year":"2007","unstructured":"de Gannes, G. C. et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch. Dermatol. 143, 223\u2013231 (2007).","journal-title":"Arch. Dermatol."},{"key":"BFnrgastro2012125_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko, J. M., Gottlieb, A. B. & Kerbleski, J. F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20, 100\u2013108 (2009).","journal-title":"J. Dermatolog. Treat."},{"key":"BFnrgastro2012125_CR57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1699-258X(08)71810-2","volume":"4","author":"B Perez-Zafrilla","year":"2008","unstructured":"Perez-Zafrilla, B., Angel Descalzo, M. & Carmona, L. Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy [Spanish]. Reumatol. Clin. 4, 90\u201395 (2008).","journal-title":"Reumatol. Clin."},{"key":"BFnrgastro2012125_CR58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D331C9H7FX","volume":"16","author":"E Beccastrini","year":"2010","unstructured":"Beccastrini, E., Squatrito, D., Emmi, G., Fabbri, P. & Emmi, L. Alopecia areata universalis during off-label treatment with infliximab in a patient with Behcet disease. Dermatol. Online J. 16, 15 (2010).","journal-title":"Dermatol. Online J."},{"key":"BFnrgastro2012125_CR59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000162180","volume":"217","author":"Y Chaves","year":"2008","unstructured":"Chaves, Y. et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217, 380 (2008).","journal-title":"Dermatology"},{"key":"BFnrgastro2012125_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","volume":"33","author":"LA Doyle","year":"2011","unstructured":"Doyle, L. A. et al. Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am. J. Dermatopathol. 33, 161\u2013166 (2011).","journal-title":"Am. J. Dermatopathol."},{"key":"BFnrgastro2012125_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/03009740902922612","volume":"38","author":"SA Exarchou","year":"2009","unstructured":"Exarchou, S. A., Voulgari, P. V., Markatseli, T. E., Zioga, A. & Drosos, A. A. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand. J. Rheumatol. 38, 328\u2013331 (2009).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrgastro2012125_CR62","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","volume":"25","author":"M Ferran","year":"2011","unstructured":"Ferran, M., Calvet, J., Almirall, M., Pujol, R. M. & Maymo, J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents: report of five cases and review of the literature. J. Eur. Acad. Dermatol. Venereol. 25, 479\u2013484 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFnrgastro2012125_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2310\/7750.2008.07095","volume":"13","author":"C Kirshen","year":"2009","unstructured":"Kirshen, C. & Kanigsberg, N. Alopecia areata following adalimumab. J. Cutan. Med. Surg. 13, 48\u201350 (2009).","journal-title":"J. Cutan. Med. Surg."},{"key":"BFnrgastro2012125_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annder.2011.01.047","volume":"138","author":"E Le Bidre","year":"2011","unstructured":"Le Bidre, E. et al. Alopecia areata during anti-TNF alpha therapy: nine cases [French]. Ann. Dermatol. Venereol. 138, 285\u2013293 (2011).","journal-title":"Ann. Dermatol. Venereol."},{"key":"BFnrgastro2012125_CR65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/09273940802596559","volume":"17","author":"Y Pan","year":"2009","unstructured":"Pan, Y. & Rao, N. A. Alopecia areata during etanercept therapy. Ocul. Immunol. Inflamm. 17, 127\u2013129 (2009).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"BFnrgastro2012125_CR66","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000113945","volume":"216","author":"N Pelivani","year":"2008","unstructured":"Pelivani, N., Hassan, A. S., Braathen, L. R., Hunger, R. E. & Yawalkar, N. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 216, 320\u2013323 (2008).","journal-title":"Dermatology"},{"key":"BFnrgastro2012125_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/s10165-009-0232-7","volume":"20","author":"K Fujikawa","year":"2010","unstructured":"Fujikawa, K. et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod. Rheumatol. 20, 86\u201389 (2010).","journal-title":"Mod. Rheumatol."},{"key":"BFnrgastro2012125_CR68","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","volume":"10","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals, M., Brito-Zeron, P., Cuadrado, M. J. & Khamashta, M. A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr. Rheumatol. Rep. 10, 442\u2013448 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrgastro2012125_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jbspin.2004.05.008","volume":"71","author":"CH Roux","year":"2004","unstructured":"Roux, C. H., Brocq, O., Albert, C. B. V. & Euller-Ziegler, L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 71, 444\u2013445 (2004).","journal-title":"Joint Bone Spine"},{"key":"BFnrgastro2012125_CR70","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie, M. et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7, R666\u2013R676 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrgastro2012125_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12016-011-8262-2","volume":"42","author":"I Pontikaki","year":"2012","unstructured":"Pontikaki, I. et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin. Rev. Allergy Immunol. 42, 131\u2013134 (2012).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrgastro2012125_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","volume":"125","author":"S Vermeire","year":"2003","unstructured":"Vermeire, S. et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125, 32\u201339 (2003).","journal-title":"Gastroenterology"},{"issue":"Suppl. 61","key":"BFnrgastro2012125_CR73","first-page":"S60","volume":"138","author":"W Van Moerkercke","year":"2010","unstructured":"Van Moerkercke, W. et al. Anti-TNFa induced severe arthralgia as a manifestation of autoimmunity? Gastroenterology 138 (Suppl. 61), S60\u2013S61 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012125_CR74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.rhu.0000250241.91842.b6","volume":"12","author":"M Rozenbaum","year":"2006","unstructured":"Rozenbaum, M., Boulman, N., Slobodin, G., Ayubkhanov, E. & Rosner, I. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J. Clin. Rheumatol. 12, 269\u2013271 (2006).","journal-title":"J. Clin. Rheumatol."},{"key":"BFnrgastro2012125_CR75","doi-asserted-by":"publisher","unstructured":"Fok, K. C., Ng, W. W., Henderson, C. J. & Connor, S. J. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J. Crohns Colitis http:\/\/dx.doi.org\/10.1016\/j.crohns.2012.01.008 .","DOI":"10.1016\/j.crohns.2012.01.008"},{"key":"BFnrgastro2012125_CR76","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.arbres.2010.05.011","volume":"47","author":"L Gifre","year":"2011","unstructured":"Gifre, L. et al. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch. Bronconeumol. 47, 208\u2013212 (2011).","journal-title":"Arch. Bronconeumol."},{"key":"BFnrgastro2012125_CR77","first-page":"1054","volume":"27","author":"JI Shin","year":"2009","unstructured":"Shin, J. I. & Kim, D. S. Development of sarcoidosis during anti-TNF-alpha treatment: what is the mechanism? Clin. Exp. Rheumatol. 27, 1054 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrgastro2012125_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","volume":"42","author":"D Tong","year":"2012","unstructured":"Tong, D., Manolios, N., Howe, G. & Spencer, D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Int. Med. J. 42, 89\u201394 (2012).","journal-title":"Int. Med. J."},{"key":"BFnrgastro2012125_CR79","doi-asserted-by":"publisher","unstructured":"Croft, A. P. et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin. Rheumatol. http:\/\/dx.doi.org\/10.1007\/s10067-011-1933-9 .","DOI":"10.1007\/s10067-011-1933-9"},{"key":"BFnrgastro2012125_CR80","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","volume":"250","author":"RJ Erckens","year":"2012","unstructured":"Erckens, R. J., Mostard, R. L., Wijnen, P. A., Schouten, J. S. & Drent, M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 250, 713\u2013720 (2012).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"BFnrgastro2012125_CR81","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461\u20131463 (2006).","journal-title":"Science"},{"key":"BFnrgastro2012125_CR82","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/gene.2008.55","volume":"9","author":"VE Garcia","year":"2008","unstructured":"Garcia, V. E. et al. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun. 9, 546\u2013555 (2008).","journal-title":"Genes Immun."},{"key":"BFnrgastro2012125_CR83","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","volume":"122","author":"F Capon","year":"2007","unstructured":"Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201\u2013206 (2007).","journal-title":"Hum. Genet."},{"key":"BFnrgastro2012125_CR84","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273\u2013290 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrgastro2012125_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"RP Nair","year":"2009","unstructured":"Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199\u2013204 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012125_CR86","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.gene.6364451","volume":"9","author":"M Chang","year":"2008","unstructured":"Chang, M. et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun. 9, 176\u2013181 (2008).","journal-title":"Genes Immun."},{"key":"BFnrgastro2012125_CR87","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ng.175","volume":"40","author":"JC Barrett","year":"2008","unstructured":"Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955\u2013962 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012125_CR88","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ng.717","volume":"42","author":"A Franke","year":"2011","unstructured":"Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118\u20131125 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012125_CR89","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079107","volume":"411","author":"JP Hugot","year":"2001","unstructured":"Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599\u2013603 (2001).","journal-title":"Nature"},{"key":"BFnrgastro2012125_CR90","doi-asserted-by":"publisher","first-page":"e1000041","DOI":"10.1371\/journal.pgen.1000041","volume":"4","author":"Y Liu","year":"2008","unstructured":"Liu, Y. et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4, e1000041 (2008).","journal-title":"PLoS Genet."},{"key":"BFnrgastro2012125_CR91","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1586\/1744666X.4.5.565","volume":"4","author":"SJ Schrodi","year":"2008","unstructured":"Schrodi, S. J. Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. Expert Rev. Clin. Immunol. 4, 565\u2013571 (2008).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"BFnrgastro2012125_CR92","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/sj.jid.5700739","volume":"127","author":"N Morar","year":"2007","unstructured":"Morar, N., Cookson, W. O., Harper, J. I. & Moffatt, M. F. Filaggrin mutations in children with severe atopic dermatitis. J. Invest. Dermatol. 127, 1667\u20131672 (2007).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrgastro2012125_CR93","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng1767","volume":"38","author":"CN Palmer","year":"2006","unstructured":"Palmer, C. N. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441\u2013446 (2006).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012125_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1529-8019.2010.01303.x","volume":"23","author":"KC Duffin","year":"2010","unstructured":"Duffin, K. C., Woodcock, J. & Krueger, G. G. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol. Ther. 23, 101\u2013113 (2010).","journal-title":"Dermatol. Ther."},{"key":"BFnrgastro2012125_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/gene.2009.11","volume":"10","author":"JT Elder","year":"2009","unstructured":"Elder, J. T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 10, 201\u2013209 (2009).","journal-title":"Genes Immun."},{"key":"BFnrgastro2012125_CR96","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ng.313","volume":"41","author":"R de Cid","year":"2009","unstructured":"de Cid, R. et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat. Genet. 41, 211\u2013215 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012125_CR97","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1084\/jem.192.9.1353","volume":"192","author":"D Gershov","year":"2000","unstructured":"Gershov, D., Kim, S., Brot, N. & Elkon, K. B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192, 1353\u20131364 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrgastro2012125_CR98","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000237385","volume":"111","author":"CA Casiano","year":"1996","unstructured":"Casiano, C. A. & Tan, E. M. Recent developments in the understanding of antinuclear antibodies. Int. Arch. Allergy Immunol. 111, 308\u2013313 (1996).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"BFnrgastro2012125_CR99","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.cyto.2011.08.026","volume":"56","author":"M Postal","year":"2011","unstructured":"Postal, M. & Appenzeller, S. The role of tumor necrosis factor-alpha (TNF-\u03b1) in the pathogenesis of systemic lupus erythematosus. Cytokine 56, 537\u2013543 (2011).","journal-title":"Cytokine"},{"key":"BFnrgastro2012125_CR100","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V. & Banchereau, J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl Acad. Sci. USA 102, 3372\u20133377 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2012125_CR101","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/art.22811","volume":"56","author":"S Dass","year":"2007","unstructured":"Dass, S., Vital, E. M. & Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715\u20132718 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrgastro2012125_CR102","first-page":"996","volume":"27","author":"TE Markatseli","year":"2009","unstructured":"Markatseli, T. E., Kaltsonoudis, E. S., Voulgari, P. V., Zioga, A. & Drosos, A. A. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin. Exp. Rheumatol. 27, 996\u2013998 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrgastro2012125_CR103","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/09546630701691236","volume":"19","author":"A Balato","year":"2008","unstructured":"Balato, A., La Bella, S., Gaudiello, F. & Balato, N. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. J. Dermatolog. Treat. 19, 182\u2013184 (2008).","journal-title":"J. Dermatolog. Treat."},{"key":"BFnrgastro2012125_CR104","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000141958","volume":"217","author":"D Firmin","year":"2008","unstructured":"Firmin, D., Roguedas, A. M., Lemasson, G., Abgrall, J. F. & Misery, L. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 217, 203\u2013206 (2008).","journal-title":"Dermatology"},{"key":"BFnrgastro2012125_CR105","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","volume":"90","author":"D Ellinghaus","year":"2012","unstructured":"Ellinghaus, D. et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90, 636\u2013647 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrgastro2012125_CR106","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1136\/gut.2007.135053","volume":"57","author":"T Kobayashi","year":"2008","unstructured":"Kobayashi, T. et al. IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682\u20131689 (2008).","journal-title":"Gut"},{"key":"BFnrgastro2012125_CR107","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ibd.20339","volume":"14","author":"J Seiderer","year":"2008","unstructured":"Seiderer, J. et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 14, 437\u2013445 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2012125_CR108","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1067\/mai.2000.106484","volume":"105","author":"DY Leung","year":"2000","unstructured":"Leung, D. Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Immunol. 105, 860\u2013876 (2000).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrgastro2012125_CR109","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/art.27203","volume":"62","author":"HL Ma","year":"2010","unstructured":"Ma, H. L. et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 62, 430\u2013440 (2010).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:30:04Z","timestamp":1687555804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2012.125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,3]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFnrgastro2012125"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2012.125","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950078.793454012","asserted-by":"object"}]},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,3]]}}}